Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Entrada Therapeutics announces positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45.
Covered in this story
Call it yourself
No calls on $TRDA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Entrada Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.